Navigation Links
Combination of 2 novel anti-cancer agents may help fight CML resistant to current therapy
Date:5/29/2008

Virginia Commonwealth University Massey Cancer Center researchers have identified that a combination of novel anti-cancer compounds is able to kill chronic myelogenous leukemia cells previously resistant to conventional forms of therapy.

Chronic myelogenous leukemia, or CML, is a cancer of the bone marrow caused by a specific genetic abnormality and is one of the more common forms of leukemia. Imatinib mesylate, or Gleevec, is a highly effective anti-cancer agent that has revolutionized the course of therapy for patients with CML. It works by inhibiting the activity of a mutant protein, known as Bcr/Abl, which is responsible for the disease. However, despite initial success, patients eventually become resistant to imatinib mesylate, often through the development of further mutations in the Bcr/Abl protein.

According to Steven Grant, M.D., Masseys associate director for translational research and co-leader of the cancer centers cancer cell biology program, and senior author of the study, resistance to imatinib mesylate prompted the search for newer agents that are active against the mutated forms of Bcr/Abl. Such agents include MK-0457, a Bcr/Abl kinase inhibitor that also targets another protein called an aurora kinase. Aurora kinase plays an important role in mitosis and cell division. In preclinical studies, MK-0457 is active against the T315I Bcr/Abl mutation, a major cause of imatinib resistance, and has shown promise in early clinical trials, Grant said.

In this study, Grant and colleagues examined the effects of combining MK-0457 with vorinostat, a novel targeted agent that has recently been approved for the treatment of cutaneous T-cell lymphoma. They found that this combination leads to a dramatic induction of apoptosis, or programmed cell death in CML cells, including imatinib-resistant cells bearing the T315I or other mutations. The article was pre-published as a First Edition Paper in Blood, the journal of the American Soci
'/>"/>

Contact: Sathy Achia Abraham
sbachia@vcu.edu
804-827-0890
Virginia Commonwealth University
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Combination therapy reverses effects of portal hypertension in rats
3. Combination vaccines okay for infants, study shows
4. Antidepressants and painkillers - a dangerous combination
5. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Drug combination might offer hope for patients deadly brain tumors
8. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
9. Combination targets: some drugs may work best when they work together
10. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
11. Quality Control: Nissan Quest to Feature micronAir(R) Combination Cabin Air Filters
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3New technique can help diagnose mesothelioma 55087 1New technique can help diagnose mesothelioma 55087 2U M researchers discover therapeutic target that could help patients with pulmonary fibrosis 55083 1U M researchers discover therapeutic target that could help patients with pulmonary fibrosis 55083 2Some brain tumors may be mediated by tiny filament on cells 9671 1Some brain tumors may be mediated by tiny filament on cells 9671 2Some brain tumors may be mediated by tiny filament on cells 9671 3Some brain tumors may be mediated by tiny filament on cells 9671 4